Takaha Pharma Co. Ltd.

Takaha Pharma Co. Ltd., a small clinical-stage drug development company, was incorporated in Feb 14, 2017 in Tokyo as a 100% subsidiary of StaGen Co., Ltd . A new drug, ATP enhancer was developed by the advanced genome-analysis technology of StaGen, and Takaha Pharma succeeds the project and proceeds clinical trials.

Our company aims to develop ATP (energy) enhancing drugs which cover a wide range of diseases including mitochondrial disease, Parkinson’s disease and Alzheimer’s disease.Our patents for ATP enhancers cover at least 9 different combinations of XOR inhibitors and hypoxanthine resources that have been granted in US, China, Japan and other countries.